Johnson & Johnson is the latest Big Pharma company that has vowed to open its clinical trial data vaults to the public, and to help it do that, it's enlisting the help of Yale University.
Some new data on the prostate cancer drug Xtandi promises to heat up competition with Johnson & Johnson's Zytiga. Medivation and its partner Astellas Pharma unveiled final data from a late-stage trial showing that Xtandi prolonged patients' lives and delayed tumor growth when used before chemotherapy.
Johnson & Johnson persuaded the Louisiana Supreme Court to toss a $257 million verdict against the company in a Risperdal marketing case, a big win in the company's multibillion-dollar fight with state and federal authorities.
Two more advances in insulin pump technology this week offer glimpses of what could soon be an actual artificial pancreas, the combination insulin pump and glucose monitor long desired in the diabetes market.
Twenty years after setting out to create an implantable artificial pancreas to treat diabetes, a pharmacy professor at De Montfort University in Leicester, England, says she'll be ready to begin human trials of the device in 2016, according to a press release from the university.
Following a lengthy waiting period for FDA approval, Animas--Johnson & Johnson's diabetes division--launched its newest combination insulin pump and continuous glucose monitoring device in Canada.
Big Pharma never lost the black eye it earned over the years for neglecting the diseases of poor countries as the industry catered largely to the needs of the developed world. But some of its biggest players are trying.
Johnson & Johnson has been working for nearly four years to overcome manufacturing problems at its key over-the-counter products plant in the U.S. and get the facility reopened. In a new sign that it is getting those problems behind it, even before the plant reopens, the drugmaker says the OTC unit posted a nearly 20% jump in U.S. sales last year as it got products like Tylenol and Motrin back in the hands of consumers.
J&J's new innovation group has signed up to work with Jim Allison, the noted cancer drug researcher who was lured away from Memorial Sloan-Kettering in late 2012 to head up a new collaboration at MD Anderson in Texas aimed at developing a new generation of cancer immunotherapies.
Johnson & Johnson med tech sales produced solid gains in 2013 as a whole, but divisions such as diabetes care and diagnostics slumped in Q4.